3-Year Overall Survival for Patients with Advanced NSCLC Treated with Pembrolizumab

被引：0
|
作者：
Hellmann, Matthew D. [1 ]
Leighl, Natasha B. [2 ]
Hui, Rina [3 ,4 ]
Carcereny, Enric [5 ]
Felip, Enriqueta [6 ,7 ]
Ahn, Myung-Ju [8 ]
Eder, Joseph Paul [9 ]
Balmanoukian, Ani S. [10 ]
Aggarwal, Charu [11 ]
Horn, Leora [12 ]
Patnaik, Amita [13 ]
Gubens, Matthew A. [14 ]
Ramalingam, Suresh S. [15 ]
Lubiniecki, Gregory M. [16 ]
Zhang, Jin [16 ]
Piperdi, Bilal [16 ]
Garon, Edward B. [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Westmead Hosp, Sydney, NSW, Australia
[4] Univ Sydney, Sydney, NSW, Australia
[5] Catalan Inst Oncol Badalona, Badalona, Spain
[6] Vall Hebron Univ Hosp, Barcelona, Spain
[7] Vall Hebron Inst Oncol, Barcelona, Spain
[8] Samsung Med Ctr, Seoul, South Korea
[9] Yale Univ, New Haven, CT USA
[10] Angeles Clin & Res Inst, Los Angeles, CA USA
[11] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[12] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[13] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
[15] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [21] HEALTHCARE RESOURCE UTILIZATION IN PATIENTS RECEIVING PEMBROLIZUMAB OR DOCETAXEL WITH PREVIOUSLY TREATED ADVANCED NSCLC
    Huang, M.
    Pellissier, J.
    Liao, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A755 - A755
  • [22] C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients with Advanced NSCLC Treated with First Line Pembrolizumab Monotherapy
    Shibata, Y.
    Kato, T.
    Shimokawaji, T.
    Yamada, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S698 - S698
  • [23] Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
    Si, Lu
    Zhang, Xiaoshi
    Shu, Yongqian
    Pan, Hongming
    Wu, Di
    Liu, Jiwei
    Mao, Lili
    Wang, Xuan
    Wen, Xizhi
    Gu, Yanhong
    Zhu, Lingjun
    Lan, Shijie
    Cai, Xin
    Diede, Scott J.
    Dai, Haiyan
    Niu, Cuizhen
    Li, Jianfeng
    Guo, Jun
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [24] Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade
    Jain, Aditya
    Zhang, Shijia
    Shanley, Ryan M.
    Fujioka, Naomi
    Kratzke, Robert A.
    Patel, Manish R.
    Kulkarni, Amit A.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (05) : 1225 - 1232
  • [25] A personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a care in Southern Thailand
    Nanthamongkolkul, Kulisara
    Taweerat, Pacharadol
    Jiamset, Ingporn
    [J]. OBSTETRICS & GYNECOLOGY SCIENCE, 2023, 66 (03) : 198 - 207
  • [26] Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade
    Aditya Jain
    Shijia Zhang
    Ryan M. Shanley
    Naomi Fujioka
    Robert A. Kratzke
    Manish R. Patel
    Amit A. Kulkarni
    [J]. Cancer Immunology, Immunotherapy, 2023, 72 : 1225 - 1232
  • [27] Obesity is Associated With Greater Overall Survival in Patients With Metastatic NSCLC Receiving First-Line Pembrolizumab
    Thomson, F.
    Stratton, C.
    Phillips, I.
    Mackean, M.
    Barrie, C.
    Campbell, S.
    Tufail, A.
    Maclennan, K.
    Evans, T.
    Stares, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S965 - S966
  • [28] STRUCTURAL CHARACTERISTICS IN TUMOR AND LYMPH NODES AS PREDICTORS OF 3-YEAR METASTASIS-FREE SURVIVAL IN SURGICALLY TREATED NSCLC
    Sellmer, L.
    Kovacs, J.
    Neumann, J.
    Kiefl, R.
    Kauffmann-Guerrero, D.
    Schneider, C.
    Tufman, A.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A34 - A34
  • [29] Risk scoring system to predict 3-year survival in patients treated for asymptomatic carotid stenosis
    Alcocer, Francisco
    Mujib, Marjan
    Lowman, Bruce
    Patterson, Mark A.
    Passman, Marc A.
    Matthews, Thomas C.
    Jordan, William D.
    [J]. JOURNAL OF VASCULAR SURGERY, 2013, 57 (06) : 1576 - 1580
  • [30] Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC
    Hellmann, Matthew D.
    Garon, Edward B.
    Gandhi, Leena
    Hui, Rina
    Zhang, Jin
    Rangwala, Reshma
    Lubiniecki, Gregory
    Rizvi, Naiyer A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S270 - S270
12345